Saturday, July 24
Lounge – 12:00pm – Ultragenyx Q&A: A LC-FAOD Treatment from Ultragenyx & Available Resources
About the Speaker
Neil James is an experienced commercial leader in the pharmaceutical and biotechnology industry, with over 30 years of global commercial experience in a broad range of disease states. For the past 15+ years Neil has focused exclusively on rare disease with a focus on inborn errors of metabolism. Neil joined BioMarin in 2010 where initially he led PKU commercialization and early stage development work before leading global development in Duchenne Muscular Dystrophy and MPS disorders. Neil joined Ultragenyx early in 2018 upon which he launched a treatment for XLH, a rare and debilitating bone disorder, before assuming the role of Vice President, Marketing & Sales with commercialization responsibility for LC-FAOD and MPS VII treatments.
Neil formerly served as a volunteer Board Director of the National PKU Alliance from 2013 -2019 and currently serves as a co-chair of the association’s Scientific Advisory Board.